OrthoPediatrics Corp (NASDAQ: KIDS) is a medical device company that designs, manufactures, and sells implants, instruments, and specialty bracing solutions exclusively for children with orthopedic conditions. Revenue comes from direct sales and distributor arrangements across three product categories: trauma and deformity, scoliosis, and sports medicine and other. Trauma and deformity is the largest segment at 70% of FY2025 net revenue ($166.3M), followed by scoliosis at 28% ($66.0M), with the remainder from sports medicine. Total net revenue was $236.3M in FY2025, up 15% from $204.7M in FY2024. The U.S. accounts for 79% of revenue ($186.4M in FY2025), with international markets at 21% ($49.9M) across more than 75 countries. The company sells through a direct sales force in the U.S. and a mix of direct sales agencies and independent stocking distributors internationally. David R. Bailey serves as President and CEO. The company carries $50M of 4.75% Convertible Senior Notes due 2030 and a term loan facility, and has reported net losses in both FY2025 ($39.6M) and FY2024 ($37.8M).

Revenue model

Transactional product sales of implants, instruments, and specialty bracing to hospitals and surgeons. U.S. sales go through a direct sales force; international sales use independent stocking distributors (who manage hospital billing relationships) and direct sales agencies paid on commission in select markets including the UK, Australia, Germany, and Canada.

Products and services

Three product categories: (1) trauma and deformity implants and instruments, (2) scoliosis systems including the VerteGlide growth guidance system (FDA-cleared, beta-launched Q3 2025) and Active Growing Implants (eLLi, Breakthrough Device designation received), and (3) sports medicine and other, which includes specialty bracing solutions from Boston O&P (acquired January 5, 2024). The company also runs clinical education programs and surgical workshops for residents and fellows.

Customers and end markets

Pediatric orthopedic surgeons and hospitals treating children with orthopedic conditions including scoliosis, fractures, limb deformities, and ACL injuries. End demand is driven by the pediatric patient population requiring orthopedic intervention.

Value-chain role

Medical device designer and manufacturer positioned between component suppliers and hospital end-users. Distributes through direct sales representatives in the U.S. and a mix of sales agencies and independent stocking distributors internationally. Operates warehouses in Germany, Australia, and the Netherlands (as of FY2025). Established a legal entity in Brazil in November 2025 for direct local distribution.

Geographic exposure

U.S.: 79% of FY2025 net revenue ($186.4M). International: 21% ($49.9M) across more than 75 countries. Direct sales agency markets include UK, Ireland, Australia, New Zealand, Canada, Belgium, Netherlands, Italy, Germany, Switzerland, Austria, and Brazil (entity established November 2025).

Source: SEC 10-K, filed 2026-03-04

Industry: Surgical & Medical Instruments & Apparatus Peers: ATRION CORP Avanos Medical Inc BioLife Solutions Inc CERUS CORP Figs Inc MERIDIAN BIOSCIENCE INC Pulmonx Corp Silk Road Medical Inc UFP Technologies Inc